Medicare scrutiny of viscosupplementation claims is increasing. For orthopedic and pain management practices, that means it is no longer enough for the chart to show that a knee injection was given. The record has to show why the patient qualified for treatment and why Medicare should have paid for it.
That matters because once your billing pattern draws attention, Medicare may look beyond one claim. A contractor may review multiple charts to decide whether your practice is consistently meeting coverage rules.
OIG Oversight of Hyaluronic Acid Knee Injection Audits
Medicare may not stop at asking whether treatment happened. It may ask whether your records were strong enough to justify payment in the first place. The Office of Inspector General (OIG) is reviewing whether Medicare paid physicians for these injections in accordance with Medicare requirements.
That shifts the focus to the full patient record. The chart has to show that the patient met the applicable Local Coverage Determinations (LCD) which is Medicare’s local rule for when a treatment is covered. If the patient later received another series, the record also has to show that the repeat treatment met Medicare’s conditions for coverage.
Core Utilization Risk Factors for CMS Audits
If your practice performs these injections often, Medicare may start by looking at your billing pattern before it looks at individual charts. The Centers for Medicare & Medicaid Services, or CMS, and its contractors often use claim patterns to decide which practices to review more closely.
These are some of the patterns that can trigger that review.
1. Outlier Volume Metrics
If your practice does far more of these injections than similar practices, that can draw attention.
- Audit risk: A practice with unusually heavy hyaluronic acid use may be reviewed more closely.
- What the record should show: That each treatment decision was based on that patient’s condition, not a routine pattern.
2. Bilateral Treatment Patterns
Treating both knees may be appropriate, but the chart has to support both knees separately.
- Audit risk: Bilateral injections billed too routinely can raise questions if the record does not support treatment of both knees.
- What the record should show: Separate findings for each knee, including symptoms, exam findings, and why both knees were treated that day.
3. Rapid-Cycle Re-treatment
A repeat series is not automatically covered just because time has passed.
- Audit risk: Medicare generally covers one series of HA injections per knee every six months, and some MACs explicitly prohibit more frequent serial injections unless clinical need is clearly demonstrated. Claims falling outside that window without strong documentation to support an exception are highly vulnerable on review.
- What the record should show: That at least six months have elapsed since the prior series, that the earlier treatment produced measurable improvement in pain and function, and that symptoms have since returned or worsened. Vague references to “recurrent pain” without specific functional details are unlikely to survive audit scrutiny.
4. Electronic Health Record (EHR) Cloning
This is a simple documentation problem that can turn into a payment problem.
- Audit risk: Templated or copied notes can make the record look unsupported, even when treatment occurred.
- What the record should show: An encounter-specific assessment with current symptoms, current findings, and a patient-specific basis for the injection.
Aligning with Medicare Requirements for HA Injections
Once a claim is under review, the question becomes simple. Does the chart match Medicare’s coverage rules?
To withstand hyaluronic acid knee injection audits, the chart has to match Medicare’s coverage rules. A diagnosis of osteoarthritis by itself is not enough. The record has to show why the patient qualified for treatment at that point in care.
1. Formalizing Objective Evidence and Diagnostic Support
If the chart does not show clear proof of knee osteoarthritis, the claim is harder to defend.
- Document symptomatic knee osteoarthritis, not just a diagnosis label.
- Include imaging support such as joint space narrowing, osteophytes, subchondral sclerosis, or subchondral cysts.
- Tie those imaging findings to the patient’s current pain and functional limits.
- Show why the patient’s current presentation supports treatment now.
2. Meeting the Three-Month Conservative Therapy Requirement
Medicare usually expects the chart to show that simpler treatment was tried first.
- Document at least three months of conservative therapy, unless there is a clear reason it could not be tried.
- Include non-drug treatment such as physical therapy, exercise, weight management, bracing, or cane use when applicable.
- Include medication history such as acetaminophen, nonsteroidal anti-inflammatory drugs, or topical agents when applicable.
- Show that these measures failed, were not tolerated, or were contraindicated.
3. Documenting Failed Non-Surgical Interventions
It is not enough to say conservative care failed. The record has to show what was tried and why it did not work.
- Identify what conservative measures were tried before the injection.
- Document why those measures did not provide enough relief.
- Include any contraindication or failure related to steroid injections when required by the applicable policy.
- Avoid vague statements like “failed conservative care” without visit-specific support.
4. Validating Repeat Series Compliance and Functional Improvement
A later series needs its own support. Medicare may ask whether the first round actually helped.
- Confirm that at least six months have passed since the prior series.
- Document that symptoms returned after the earlier benefit wore off.
- Show that the prior series improved pain and function.
- Make clear that the patient still meets the initial coverage criteria before starting another series.
Proactive Risk Management and Internal Compliance Infrastructure
Protecting your practice from recoupment exposure requires a shift from reactive billing to proactive operational oversight. Internal look-back audits can help identify and correct documentation gaps before they draw federal scrutiny.
In practice, that usually means focusing on a few basic areas:
- Template review: Update electronic health record templates so they require knee-specific findings, prior treatment history, and a clear reason for treatment. This helps prevent copied notes that all look the same.
- Internal chart checks: Periodically review a sample of paid claims to see whether the documentation would hold up if Medicare reviewed it today.
- Treatment rationale: Make sure the note explains why this treatment was used instead of, or after, other options such as corticosteroid injections.
- Staff training: Train clinical and billing staff on the three-month conservative treatment rule, repeat-series timing, and the need for separate support for each knee when bilateral treatment is billed.
Frequently Asked Questions
What is a Medicare coverage requirement for hyaluronic acid HA injections for knee osteoarthritis?
Medicare coverage for HA injections generally requires a documented diagnosis of symptomatic osteoarthritis confirmed by imaging, a failure of at least three months of conservative non-surgical treatment, and documentation that the patient is not a candidate for or has failed other interventions like corticosteroid injections.
Are hyaluronic acid injections covered by insurance?
Most commercial insurance plans and Medicare Part B cover HA injections when medical necessity is established according to their specific policies. However, many private payers are following Medicare’s lead in tightening their coverage criteria and increasing scrutiny of these claims.
Are hyaluronic acid injections FDA approved?
Yes, various HA products are FDA-approved as medical devices for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.
Addressing Audit Risks in Orthopedic and Pain Management Practices
Managing hyaluronic acid knee injection audits starts with documentation that matches Medicare’s coverage rules. For orthopedic and pain management practices, the main risk is not the injection itself. It is whether the record supports medical necessity, prior conservative treatment, repeat-series timing, and a patient-specific clinical rationale.
Nichols Weitzner Thomas LLP helps providers review documentation protocols, assess audit exposure, and strengthen their response during post-payment review. To discuss your practice’s audit risk, contact one of our healthcare attorneys today.
This article is for informational purposes only and does not constitute legal advice. For guidance specific to your situation, consult with the healthcare attorneys at Nichols Weitzner Thomas LLP.
